Coverage generosity of novel anti‐rheumatic drugs in Medicare Advantage and stand‐alone Part D plans
The growing exclusions of self-administered DMARDs across several mechanisms of action and heterogeneity in coverage by plan type suggest potential barriers to accessing optimal RA treatments. Further monitoring of formulary adequacy and research into the clinical impacts of formulary exclusions are warranted.
Authors
- Robert W. Corty (ORCID: https://orcid.org/0000-0002-6787-9051)
- Youngmin Kwon (ORCID: https://orcid.org/0000-0001-8037-5758)
- Stacie B. Dusetzina (ORCID: https://orcid.org/0000-0002-3907-9196)
Institutions
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1002/art.70132
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00